title: Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA).
abstract: A prospective study was made to seek for a convenient biomarker to predict progression of bone destruction (PBD) in early stages of rheumatoid arthritis (ERA). All participated patients had definite RA and their radiographic stages were mild less than stage II of the Steinbrocker classification, naïve for treatment of any DMARDs or corticosteroids. After the entry, they were treated according to the 2002 ACR management guideline for RA. The candidate biomarkers (RF-IgM, RF-IgG, CARF, ACPA, CRP, ESR, NTx, MMP-3, IL-6 and osteopontin) were measured at the entry. PBD was assessed radiographically by interval changes in the modified Sharp scores (ΔSHS) for 24 months. The associations between ΔSHS and baseline biomarkers were assessed statistically by multivariate regression analyses. Both the baseline ACPA and IL-6 levels correlated with PBD, suggesting that they could predict PBD in ERA.
authors.affiliation: Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, 2-1 Kidohigashi-machi, Kawachinagano City, Osaka 586-8521, Japan. saekiy@ommc-hp.jp
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Saeki
authors.forename: Eriko
authors.initials: E
authors.lastname: Kudo-Tanaka
authors.forename: Shiro
authors.initials: S
authors.lastname: Ohshima
authors.forename: Masato
authors.initials: M
authors.lastname: Matsushita
authors.forename: So-ichiro
authors.initials: S
authors.lastname: Tsuji
authors.forename: Yu-ichi
authors.initials: Y
authors.lastname: Maeda
authors.forename: Maiko
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Akane
authors.initials: A
authors.lastname: Watanabe
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Katada
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Harada
authors.forename: Kenji
authors.initials: K
authors.lastname: Ichikawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Suenaga
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Ohta
authors.forename: Shigeto
authors.initials: S
authors.lastname: Tohma
mesh_terms: D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers; D018450:Disease Progression; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology*; D011446:Prospective Studies; D011859:Radiography; D012044:Regression Analysis; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; C508600:IL6 protein, human; D015850:Interleukin-6; D010456:Peptides, Cyclic; D014409:Tumor Necrosis Factor-alpha; C487763:cyclic citrullinated peptide